To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.
General Information
DRAVP ID DRAVPe01768
Peptide Name ATN-161
Sequence PHSCN
Sequence Length 5
UniProt ID No entry found
Source Synthetic construct
Activity Information
Target Organism SARS-CoV-2
Assay ELISA
Activity
Hemolytic Activity No hemolysis information or data found in the reference(s) presented in this entry
Cytotoxicity No cytotoxicity information found in the reference(s) presented
Binding Target Not found
Mechanism The peptide inhibits the spike protein interaction with α5β1 integrin and the interaction between α5β1 integrin and ACE2.
Structure Information
PDB ID None
Predicted Structure Download No predicted structure available
Linear/Cyclic Linear
N-terminal Modification Acylation
C-terminal Modification Amidation
Other Modification None
Stereochemistry L
Physicochemical Information
Formula C21H32N8O8S
Absent amino acids ADEFGIKLMQRTVWY
Common amino acids CHNPS
Mass 556.59
Pl 7.12
Basic residues 1
Acidic residues 0
Hydrophobic residues 0
Net charge 1
Boman Index -1342
Hydrophobicity -132
Aliphatic Index 0
Half Life
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 3
Literature Information
Literature 1
Title The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.
Pubmed ID 33102950
Reference JACC Basic Transl Sci. 2021 Jan;6(1):1-8.
Author Beddingfield BJ, Iwanaga N, Chapagain PP, Zheng W, Roy CJ, Hu TY, Kolls JK, Bix GJ.
To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.